Item 7.01 Regulation FD Disclosure.
Pursuant to Regulation FD, PLx Pharma Inc. (the "Company") hereby furnishes the
Corporate Presentation that Natasha Giordano, the Company's President and Chief
Executive Officer, and Rita O'Connor, the Company's Chief Financial Officer,
will present to investors on or after September 21, 2021. The Corporate
Presentation is attached hereto as Exhibit 99.1 and will be available on the
Company's website under the Investor Relations tab.
The information furnished by the Company pursuant to this Item 7.01, including
Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise
subject to the liability of that section, and shall not be deemed to be
incorporated by reference into any Company filing under the Securities Act of
1933, as amended, or the Exchange Act, regardless of any general incorporation
language in such filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
99.1 PLx Pharma Inc. September 2021 Corporate Presentation.
© Edgar Online, source Glimpses